Joshua Silverman insider trades: PharmaCyte Biotech (PMCB) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Joshua reports to the SEC
and 14 more companies
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 7, 2026 | PMCB | ↑ Buy | 100,000 | $0.80 | $80K | Direct | Jan 7, 2026 (0d) |
| Aug 1, 2023 | AYRO | ↓ Sell | 12,740 | $0.82 | $10K | Direct | Aug 3, 2023 (2d) |
| May 3, 2023 | AYRO | ↓ Sell | 11,927 | $0.49 | $6K | Direct | May 5, 2023 (2d) |
| Jan 30, 2023 | AYRO | ↓ Sell | 7,171 | $0.71 | $5K | Direct | Feb 3, 2023 (4d) |
| Dec 16, 2022 | SNPX | ↓ Sell10b5-1 | 19,012 | $1.17 | $22K | Direct | Dec 20, 2022 (4d) |
| Nov 1, 2022 | AYRO | ↓ Sell | 20,026 | $0.74 | $15K | Direct | Nov 3, 2022 (2d) |
| Nov 26, 2021 | MYMD | ↑ Buy | 15,000 | $6.89 | $103K | Direct | Nov 29, 2021 (3d) |
| Jun 14, 2021 | SNPX | ↑ Buy | 10,000 | $8.30 | $83K | Direct | Jun 16, 2021 (2d) |
| Jun 4, 2021 | AYRO | ↓ Sell | 39,008 | $5.17 | $202K | Direct | Jun 8, 2021 (4d) |
| Oct 16, 2020 | NTRP | ↑ Buy | 50,000 | $1.09 | $54K | Direct | Oct 20, 2020 (4d) |
| Oct 15, 2020 | NTRP | ↑ Buy | 50,000 | $1.07 | $53K | Direct | Oct 19, 2020 (4d) |
| Jun 26, 2018 | DCAR | ↑ Buy | 30,000 | $1.26 | $38K | By JNS Holdings Group LLC | Jun 26, 2018 (0d) |
| May 9, 2013 | TWFH | ↑ Buy | 344,210 | $0.19 | $67K | Indirect | May 14, 2013 (5d) |
| Dec 21, 2011 | VRNG | ↓ Sell | 9,000 | $1.16 | $10K | Indirect | Dec 22, 2011 (1d) |
| Dec 20, 2011 | VRNG | ↓ Sell | 7,400 | $1.11 | $8K | Indirect | Dec 20, 2011 (0d) |
| Dec 16, 2011 | VRNG | ↓ Sell | 1,800 | $1.08 | $2K | Indirect | Dec 19, 2011 (3d) |
| Dec 14, 2011 | VRNG | ↓ Sell | 15,701 | $1.15 | $18K | Indirect | Dec 14, 2011 (0d) |
| Dec 12, 2011 | VRNG | ↓ Sell | 2,900 | $1.21 | $4K | Indirect | Dec 13, 2011 (1d) |
| Oct 26, 2011 | VRNG | ↓ Sell | 5,000 | $1.51 | $8K | Indirect | Oct 31, 2011 (5d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PMCB insiders
Open-market trades in the last 12 months
About Joshua Silverman's insider trades
Joshua Silverman is CEO and President at PharmaCyte Biotech (PMCB). Since Oct 26, 2011, Joshua has reported 7 open-market purchases worth $479K and 12 sales worth $310K on SEC Form 4. In the last 12 months: 1 buy ($80K).
1 sale (7% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include grants and awards (56 filings), shares withheld for taxes (7 filings), option exercises (5 filings), other transactions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PMCB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.